Results 41 to 50 of about 43,229 (277)

Strategies for the treatment of Hepatitis C in an era of interferon-free therapies: what public health outcomes do we value most? [PDF]

, 2014
Objective: The expense of new therapies for HCV infection may force health systems to prioritise the treatment of certain patient groups over others.
Dillon, John, Goldberg, David, Hutchinson, Sharon J, Innes, Hamish   +3 more
core   +1 more source

Predictability of IL-28B-polymorphism on protease-inhibitor-based triple-therapy in chronic HCV-genotype-1 patients: A meta-analysis

, 2014
AIM: To investigate the predictability of interleukin-28B single nucleotide polymorphism rs12979860 with respect to sustained virological response (SVR) in chronically hepatitis C virus (HCV) genotype-1 patients treated with a protease-inhibitor and ...
Amanzada, Ahmad, Cameron, Silke, Mechie, Nicolae-Catalin, Röver, Christian   +3 more
core   +1 more source

Evaluation of the long-term outcomes of patients with hepatitis delta

Journal of Infection in Developing Countries
Objective: To evaluate the long-term outcomes of hepatitis delta patients, including cirrhosis and hepatocellular carcinoma (HCC), based on clinical and laboratory data.
Muhammet Salih Tarhan, Habip Gedik, Kadriye Kart-Yasar   +2 more
doaj   +1 more source

[Pegylation and interferons in multiple sclerosis]

Farmeconomia. Health economics and therapeutic pathways, 2016
Pegylation is a procedure used for drug development since the 1970s and consists of the conjugation of a polyethylene glycol molecule (PEG) to a drug. PEG has shown to be safe and effective in improving the pharmacokinetic and pharmacodynamic profile of drugs.
Cecilia Saleri, Diego Centonze, Giulia Vestri, Elisa Puma, Sergio Iannazzo, Luigi Giuliani, L Santoni, Pier Luigi Canonico   +7 more
openaire   +4 more sources

Long-term outcomes of direct acting antivirals in post-transplant advanced hepatitis C virus recurrence and fibrosing cholestatic hepatitis. [PDF]

, 2017
Long-term functional outcomes of sofosbuvir-based antiviral treatment were evaluated in a cohort study involving 16 Italian centres within the international compassionate use programme for post-transplant hepatitis C virus (HCV) recurrence. Seventy-three
Burra, Patrizia, Romano, Antonietta, Russo, Francesco Paolo   +2 more
core   +1 more source

A cost-utility analysis of different antiviral medicine regimens in patients with chronic hepatitis C virus genotype 1 infection [PDF]

, 2016
Background: Despite the introduction of new drug regimens with high effectiveness for the hepatitis C virus (HCV) patients, especially in HCV genotype 1, no cost-effectiveness study on the selection of the superior drug strategy in Iran has been ...
Alavian, Seyed Moayed, Kebriaeezadeh, Abbas, Keshavarz, Khosro, Lotfi, Farhad, Nikfar, Shekoufeh, Rezaei Hemami, Mohsen, Sanati, Ehsan   +6 more
core   +1 more source

Antiemesis Corticosteroids Potentiate Checkpoint Blockade Efficacy by Normalizing the Immune Microenvironment in Metastatic Murine Breast Cancer

Advanced Science, EarlyView.
Corticosteroids improve the efficacy of immune checkpoint blockade therapy in metastatic murine breast cancer. By normalizing the tumor immune microenvironment, corticosteroids reduce immunosuppressive signals, restore T‐cell function, and promote antitumor immune responses, resulting in enhanced tumor control.
John D. Martin, Koji Nagaoka, Myrofora Panagi, Akihiro Hosoi, Fotios Mpkeris, Pengwen Chen, Thahomina T. Khan, Margaret R. Martin, Changbo Sun, Chrysovalantis Voutouri, Maria Louca, Panagiotis Papageorgis, Akira Sumiyoshi, Nobuhiro Nitta, Kazuyoshi Takeda, Ichio Aoki, Kazunori Kataoka, Triantafyllos Stylianopoulos, Kazuhiro Kakimi, Horacio Cabral   +19 more
wiley   +1 more source

Validation of a questionnaire to monitor symptoms in HIV-infected patients during hepatitis C treatment

AIDS Research and Therapy, 2017
Background Clinicians are incorporating patient-reported outcomes in the management of HIV-infected persons co-infected with hepatitis C virus (HCV), but there are no validated inventories to monitor symptoms of patients during HCV therapy.
Edward R. Cachay, Craig Ballard, Bradford Colwell, Francesca Torriani, Charles Hicks, Wm. Christopher Mathews   +5 more
doaj   +1 more source

Response to pegylated interferon in a COVID‐19 positive male with metastatic jejunal neuroendocrine tumor treated with everolimus

Clinical Case Reports, 2021
A 61‐year‐old male on everolimus had chronic SARS‐CoV‐2 infection. Addition of pegylated interferon cleared viral RNA and supports combination therapy with everolimus plus interferon for COVID‐19.
Arthur E. Frankel, Wai C. Yip, Eknath Naik, Hans C. Hasselbalch   +3 more
doaj   +1 more source

Is increased hepatitis C virus case-finding combined with current or 8-week to 12-week direct-acting antiviral therapy cost-effective in UK prisons? A prevention benefit analysis [PDF]

, 2016
UNLABELLED: Prisoners have a high prevalence of hepatitis C virus (HCV), but case-finding may not have been cost-effective because treatment often exceeded average prison stay combined with a lack of continuity of care. We assessed the cost-effectiveness
Brew, Iain F., Hickman, Mathew, Hutchinson, Sharon J., Irving, William L., Mandal, Sema, Martin, Natasha K., Miners, Alec, O'Moore, Eamonn, Saksena, Sushma, Vickerman, Peter, Williamson, Joan   +10 more
core   +3 more sources